Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults
jRCT2071260039Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial in Staphylococcus aureus bloodstream infection (SABSI) comparing AZD7760 IV arm with Placebo IV arm (2 arms). Primary endpoints: Occurrence of adverse events through Day 181 and Occurrence of MAAEs, SAEs, and AESIs through Day 361. Started Jun 2026; status: active, not recruiting.
02
Drugs
AZD7760
03
Conditions
Staphylococcus aureus bloodstream infection (SABSI)
Beyond the preview
Go deeper on jRCT2071260039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260039.